Price = $475,000
The drug’s price tag reads a whopping $475,000. But Novartis has agreed with CMS on a value-based pricing framework. As part of the deal, Novartis can only recognize revenue from the drug if the patient demonstrates a clinical response by the end of the first month.
Sets a benchmark for CAR-T therapy pricing.